» Articles » PMID: 22878095

Hepatitis C Virus Entry: Role of Host and Viral Factors

Overview
Date 2012 Aug 11
PMID 22878095
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) has been considered to be a significant risk factor in developing liver associated diseases including hepatocellular carcinoma all over the world. HCV is an enveloped positive strand virus comprising a complex between genomic RNA and viral envelope glycoproteins (E1 and E2), which are anchored within host derived double-layered lipid membrane surrounding the nucleocapsid composed of several copies of core protein. HCV cell entry is the first step in infection and viral replication into host cells mainly hepatocytes. HCV cell entry is a complex process involving both the viral (envelope glycoproteins E1/E2) and host factors (cellular receptors and associated factors i.e. CD81, SR-BI, LDL-R, CLDN1, Occludin, DC-SIGN, L-SIGN and Glycosaminoglycans). Besides these the expression of certain other conditions such as polarization and EWI-2 expression inhibits the viral cell entry. Exploring the mechanism of HCV entry will help to better understand the viral life cycle and possible therapeutic targets against HCV infection including viral and host factors involved in this process. New strategies such as RNAi represents a new option for targeting the host or viral factors for prevention and therapeutic against HCV infection. In the current review we try to summarize the current knowledge about mechanism and interaction of cellular and viral factors involved in HCV cell entry and its implication as therapeutic target to inhibit HCV infection.

Citing Articles

MiR-451a attenuates hepatic steatosis and hepatitis C virus replication by targeting glycerol kinase.

Majumdar S, Chowdhury D, Chakraborty B, Chowdhury A, Datta S, Banerjee S J Transl Med. 2025; 23(1):322.

PMID: 40083012 PMC: 11907786. DOI: 10.1186/s12967-025-06286-9.


Hepatitis C Virus (HCV) Infection: Pathogenesis, Oral Manifestations, and the Role of Direct-Acting Antiviral Therapy: A Narrative Review.

Di Stasio D, Guida A, Romano A, Petruzzi M, Marrone A, Fiori F J Clin Med. 2024; 13(14).

PMID: 39064052 PMC: 11278420. DOI: 10.3390/jcm13144012.


Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients.

Abdel Allah H, Zahran W, El-Masry S, El-Bendary M, Soliman A Clin Exp Med. 2021; 22(2):257-267.

PMID: 34297238 DOI: 10.1007/s10238-021-00747-3.


Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns.

Abutaleb A, Kattakuzhy S, Kottilil S, OConnor E, Wilson E J Neurovirol. 2018; 24(6):670-678.

PMID: 30291565 PMC: 6436106. DOI: 10.1007/s13365-018-0678-5.


Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.

Petruzziello A Open Virol J. 2018; 12:26-32.

PMID: 29541276 PMC: 5842386. DOI: 10.2174/1874357901812010026.